Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges - Wikidata - wikimedia - TriplyDB

Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges

Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges

http://www.wikidata.org/entity/Q35951545

about

Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates Potent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 Protein Vaccinia virus exhibits cell-type-dependent entry characteristics.A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice Evaluation of smallpox vaccines using variola neutralization.Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund's adjuvant, and monophosphoryl lipid A TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.Smallpox vaccines: targets of protective immunity.Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.CpG DNA as a vaccine adjuvant.Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.Vaccinia virus entry/fusion complex subunit A28 is a target of neutralizing and protective antibodies Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.The smallpox vaccine induces an early neutralizing IgM response.Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses.Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.The strategic use of novel smallpox vaccines in the post-eradication world.Animal poxvirus vaccines: a comprehensive review.Recombinant Sheep Pox Virus Proteins Elicit Neutralizing Antibodies Mucosal Adjuvant Potential of Quillaja saponins and Cross-linked Dextran Microspheres, Co-administered with Liposomes Encapsulated with Tetanus Toxoid.Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant.A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice

P2860

Q27325586-1C507CC4-E901-4033-BEA4-0AF576F034EF Q27684713-70E2F4A4-5C03-4C63-B34A-C267E5700ADE Q33698769-FD655FAE-7115-48F8-988C-ACAE2C5E3A98 Q33905188-B2DCC4EE-BF20-4D67-A360-D8E46C490C81 Q33920540-57DCCF64-C081-4E3B-BEAD-D9D0018A2F45 Q33936717-6B24C097-E1C6-41E5-91C6-084180423057 Q34126697-F3F29682-F2D7-42F7-BE71-66F31FE97DC9 Q34351055-64A99F04-562E-4479-8365-7E6740D8C380 Q34414790-4D7AB493-FF4C-405A-9252-1580A3D3E729 Q34780607-268FA28B-4602-4FFD-8D74-39081E3BD0C7 Q34910424-E6722E94-7900-43D0-A42E-F888420CB01A Q35025722-AC5BA1D7-5B33-48A0-AABC-E29320FD9974 Q35152092-81768C6A-DDD4-4BAD-AF7B-2BB19C7A169C Q35339702-3BDB810E-1099-4FD4-A421-8BFBEBE7FFCE Q35948047-98EE96A0-726B-4A4A-AFB0-4731930C016A Q36487366-EB564F25-1D5E-46B8-8D57-F221A7304BD5 Q36498244-C9E4B78A-210A-4BA9-95C5-0D98270E57D8 Q36718066-E5BECD99-29CA-48B4-BCEE-3063C49D2619 Q36845650-F5DAB89D-FC59-4A11-97C7-273EE15C73BE Q37066691-D4CA8BA0-05DB-45B3-A947-80B94B64DA3D Q37125302-35D2C9E5-137B-41E1-AC6E-70DD508E3AF1 Q37169163-EB192258-15CB-4D10-B1F9-F9CB7793C7D1 Q37456873-A8BA4888-3FCD-4311-BD54-1C16DE73C1C9 Q37461110-4E5E42C0-CE53-46DB-817F-8E660177BFD6 Q37547211-17C248E8-155C-498E-8AA1-20EACFF2A9A0 Q37873932-B53FB547-C111-468F-87F3-4EF22A9F844A Q37909421-8E929DC9-C8E8-400C-BBDB-ED1B966FF671 Q38068233-F88CFA85-2783-489E-94F5-0D66A3003438 Q40684847-29B9C068-BA76-47A3-A9C3-4D98704B2A51 Q41884496-9A1C3C86-117D-496A-AE8B-EC3DB90B5D2C Q47155945-B74FB2F3-7A5D-40E5-A501-72DEFA1DD9D9 Q59127186-4338C9CA-91C1-4B62-9C23-8AF16C1F71A7

P2860

Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges

http://www.wikidata.org/entity/Q35951545

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Adjuvant-enhanced antibody res ...... ys to orthopoxvirus challenges

@ast

Adjuvant-enhanced antibody res ...... ys to orthopoxvirus challenges

@en

type

label

Adjuvant-enhanced antibody res ...... ys to orthopoxvirus challenges

@ast

Adjuvant-enhanced antibody res ...... ys to orthopoxvirus challenges

@en

prefLabel

Adjuvant-enhanced antibody res ...... ys to orthopoxvirus challenges

@ast

Adjuvant-enhanced antibody res ...... ys to orthopoxvirus challenges

@en

P1433

Q35951545-680DBA10-6E7B-4766-89A4-16540B66269D

P1476

Q35951545-DC6B9356-F255-4159-ACD5-8978D80BEF4E

P2093

Q35951545-0501C43B-35A1-4637-BE0C-E3891587B24A

Q35951545-0DC8D548-3BCB-4BE4-939C-A4DF9F63DB28

Q35951545-135527BC-4A6D-4FAC-9636-E15BCDE5ABF6

Q35951545-2C06C97F-4A26-41BD-9735-37F42F49C387

Q35951545-2D8EBE29-EC9B-4B50-84CB-5CB7B19315A7

Q35951545-5F5FDE2B-0063-45E8-A949-EA19ED766E3E

Q35951545-869FC87B-C01D-4576-BAD7-3AD80A88395D

Q35951545-AD1345FC-2486-4129-9EC5-EB0B4F71B1EC

Q35951545-E41DA69B-AF63-4417-8085-53A22C5150CF

P2860

Q35951545-0045EBD0-DC39-4810-9696-F849F84E5C3E

Q35951545-04251479-73A3-47D2-AB67-D2AF86F93C5C

Q35951545-065241C8-1F1E-4EE1-ACA4-04205261C60C

Q35951545-0B9A0712-9951-42A1-9391-ACBA15558BAA

Q35951545-117CED63-6926-4737-B6AD-7FB4AFDDA03E

Q35951545-12963DDC-4D3B-4F07-A310-933AADEEF087

Q35951545-14669250-BFC7-4A31-815E-279838C00A02

Q35951545-14972237-4814-414E-AAFA-AD011B409659

Q35951545-1B858C6E-7DB7-4C58-B5FE-C66F51359E5F

Q35951545-1C4FD30B-190F-4690-B6AC-BD2127CADFE8

P304

Q35951545-8A274FAD-0FF7-4024-8D12-08E7FC9531F2

P31

Q35951545-A0B47642-AB31-4C03-B76C-B50DFE08FD19

P356

Q35951545-86526FBD-997F-40DF-AC4C-7DF133CB1C5E

P407

Q35951545-B0032A90-2021-4001-B3DA-D78352B2C89C

P433

Q35951545-368E8EB0-1859-4C14-8940-5D0804578594

P478

Q35951545-0A8524C0-F3C5-4F80-88E8-2232C65AA3FF

P50

Q35951545-B63072B6-E57A-4A0F-87FE-BB105E4ECF4A

P577

Q35951545-EA877A69-D2F4-4486-B778-66811E53FE70

P5875

Q35951545-C5F5DF8D-AAF7-43BD-98DF-D88CDEACB91D

P698

Q35951545-15021295-DF08-447E-AE10-A2097F4F67D5

P921

Q35951545-9F48419B-0A2C-4D99-99B2-14DE1F5F3DC3

P932

Q35951545-98B5DF44-FC29-41A8-A97D-7EC3577C9830

P356

J.VACCINE.2006.12.037

P1433

P1476

Adjuvant-enhanced antibody res ...... ys to orthopoxvirus challenges

@en

P2093

Christiana N Fogg

http://www.w3.org/2001/XMLSchema#string

Dennis M Klinman

http://www.w3.org/2001/XMLSchema#string

Inger Damon

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Americo

http://www.w3.org/2001/XMLSchema#string

John W Huggins

http://www.w3.org/2001/XMLSchema#string

Patricia L Earl

http://www.w3.org/2001/XMLSchema#string

Scott K Smith

http://www.w3.org/2001/XMLSchema#string

Shlomo Lustig

http://www.w3.org/2001/XMLSchema#string

Wolfgang Resch

http://www.w3.org/2001/XMLSchema#string

P2860

Genetic and Physical Mapping of theLpsLocus: Identification of the Toll-4 Receptor as a Candidate Gene in the Critical Region

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

The looming threat of bioterrorism.

CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines.

Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction.

Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Interferon function is not required for recovery from a secondary poxvirus infection.

P304

2787-2799

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2006.12.037

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6572150

http://www.w3.org/2001/XMLSchema#string

P698

17229505

http://www.w3.org/2001/XMLSchema#string

P921

P932

1952660

http://www.w3.org/2001/XMLSchema#string